A review of potential cardiac drug-drug interactions amongst patients
presenting with cystic fibrosis exacerbation
Drug-drug interactions inducing adverse drug reactions remain a
significant, avoidable health risk to cystic fibrosis (CF) patients.
With increasingly complex CF exacerbation treatment regimens being used,
the risk of clinically important drug-drug interactions has in turn
increased. Cardiovascular medications have reportedly been commonly
implicated in severe CF exacerbation drug-drug related reactions.
Therefore, knowledge of these potential drug-drug interactions is
essential for improvement of medication safety and preventing patient
harm. Drug-drug interactions can be classified into either
pharmacokinetic or pharmacodynamic. This article, using the British
National Formulary, details the drug-drug interactions between commonly
prescribed CF exacerbation medications and cardiac medications. For each
respective drug-drug interaction, the potential consequence, management
strategy and interaction severity have been described.